Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators

Molecular Therapy

Volumn 15, Issue 1, 2007, Pages 173-182

  Robert Richard, Elodie ^a,b   Richard, Emmanuel ^a,b   Malik, Punam ^c   Ged, Cécile ^a,b   de Verneuil, Hubert ^a,b   Moreau Gaudry, François ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANKYRIN; ELONGATION FACTOR 1ALPHA; GREEN FLUORESCENT PROTEIN; PHOSPHOGLYCERATE KINASE; RETROVIRUS VECTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL PROTECTION; CONTROLLED STUDY; DEREGULATION; ERYTHROCYTE; ERYTHROCYTE DISORDER; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LENTIVIRUS VECTOR; MOUSE; NONHUMAN; PROMOTER REGION; SARCOMA VIRUS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STEM CELL GENE THERAPY; VIRAL GENE THERAPY;

MURINAE; MYELOPROLIFERATIVE SARCOMA VIRUS;

EID: 33845996970     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300030     Document Type: Article

References (42)

1. Cavazzana-Calvo, M et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288: 669-672.
2. Hacein-Bey-Abina, S et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
3. Gaspar, HB et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
4. Ragg, S et al. (2000). Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 60: 5187-5195.
5. 6benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 57: 5093-5099.
6. 6-methylguanine DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95: 3078-3084.
7. 6-benzylguanine. Biochemistry 32: 11998-12006.
8. 6-methylguanine-DNA methyltransferase mutants: Implications for drug resistance gene therapy. Hum Gene Ther 10: 2769-2778.
9. Zielske, SP, Reese, JS, Lingas, KT, Donze, JR and Gerson, SL (2003). In vivo selection of MGMT (P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest 112: 1561-1570.
10. Neff, T et al. (2003). Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 112: 1581-1588.
11. Moreau-Gaudry, F et al. (2001). High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 98: 2664-2672.
12. Richard, E et al. (2001). Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 4: 331-338.
13. Richard, E et al. (2004). Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug-selection without myeloablation. Gene Ther 2: 249-259.
14. Zielske, SP, Lingas, KT, Li, Y and Gerson, SL (2004). Limited lentiviral transgene expression with increasing copy number in an MGMT selection model: Lack of copy number selection by drug treatment. Mol Ther 9: 923-931.
15. Chung, JH, Bell, AC and Felsenfeld, G (1997). Characterisation of the chicken β-globin insulator. Proc Natl Acad Sci USA 94: 575-580.
16. Yusufzai, TM and Felsenfeld, G (2004). The 50-HS4 chicken beta-globin insulator is a CTCF dependent nuclear matrix-associated element. Proc Natl Acad Sci USA 101: 8620-8624.
17. Halene, S, Wang, L, Cooper, RM, Bockstoce, DC, Robbins, PB and Kohn, DB (1999). Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 94: 3349-3357.
18. Kumar, M, Keller, B, Makalou, N and Sutton, RE (2001). Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 12: 1893-1905.
19. Neff T Beard, BC, Peterson, LJ, Anandakumar, P, Thompson, J and Kiem, HP (2005). Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105: 997-1002.
20. Persons, DA et al. (2003). Successful treatment of murine \{beta\}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102: 506-513.
21. Gerson, SL (2004). MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307.
22. Persons, DA, Hargrove, PW, Allay, ER, Hanawa, H and Nienhuis, AW (2003). The degree of phenotypic correction of murine beta-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183.
23. Modlich, U et al. (2005). Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105: 4235-4246.
24. 6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther 13: 391-400.
25. 6-alkylguanine DNA alkyltransferases in human hematopoietic cells. Mol Cancer Ther 5: 121-128.
26. Recillas-Targa, F, Pikaart, MJ, Burgess-Beusse, B, Bell, AC, Litt, MD and West, AG (2002). Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci USA 99: 6883-6888.
27. Emery, DW, Yannaki, E, Tubb, J, Nishino, T, Li, Q and Stamatoyannopoulos, G (2002). Development of virus vectors for gene therapy of beta chain hemoglobinopathies: Flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100: 2012-2019.
28. Ramezani, A, Hawley, TS and Hawley, RG (2003). Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 101: 4717-4724.
29. Steinwaerder, DS and Lieber, A (2000). Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. Gene Ther 7: 556-567.
30. Martin-Duque, P, Jezzard, S, Kaftansis, L and Vassaux, G (2004). Direct comparison of the insulating properties of two genetic elements in an adenoviral vector containing two different expression cassettes. Hum Gene Ther 15: 995-1002.
31. Yusufzai, TM and Felsenfeld, G (2004). The 5′-HS4 chicken beta-globin insulator is a CTCF-dependent nuclear matrix-associated element. Proc Natl Acad Sci USA 101: 8620-8624.
32. Bell, AC, West, AG and Felsenfeld, G (1999). The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98: 387-396.
33. Goodrich, DW and Duesberg, PH (1990). Retroviral recombination during reverse transcription. Proc Natl Acad Sci USA 87: 2052-2056.
34. Muravyova, E et al. (2001). Loss of insulator activity by paired Su(Hw) chromatin insulators. Science 291: 495-498.
35. Salmon, P, Kindler, V, Ducrey, O, Chapuis, B, Zubler, RH and Trono, D (2000). High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood 96: 3392-3398.
36. +-derived cells from patients with paroxysmal nocturnal hemoglobinuria. Mol Ther 7: 304-316.
37. -/line cells from mobilized peripheral blood after cytokine prestimulation. Stem Cell 21: 472-480.
38. Fischer, A, Abina, SH, Thrasher, A, von Kalle, C and Cavazzana-Calvo, M (2004). LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med 350: 2526-2527.
39. Sirven, A et al. (2001). Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 3: 438-448.
40. Mizushima, S and Nagata, S (1990). pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18: 5322.
41. +CD38- human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 96: 2988-2993.
42. Richard, E et al. (2003). A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J Gen Med 5: 737-747.